Longer-term, Eisai and Biogen are hoping for further evidence to support Leqembi from the phase 3 AHEAD 3-45 trial, which ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...

The ROS-1 NSCLC current market is mainly dominated by tyrosine kinase inhibitors such as XALKORI at present and is anticipated to be dominated ...

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and ranks among the leading causes of cancer-related deaths globally. Traditional treatment methods, including surgical resection ...

datopotamab deruxtecan is one of the three lead ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ET. Company Participants. Hiroyuki Okuzawa - Representative Director, Presi ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...